

Telmisartan Market to Generate \$4,258 Million by 2027 | Growth & Key Business Strategies

Based on indication, the hypertension segment held the highest market share in 2019, accounting for around 90% of the global telmisartan market.

NE WIN SIVERS DRIVE, PROVINCE: -
PORTLAND, UNITED STATES,
September 27, 2021 /

EINPresswire.com/ -- Allied Market Research published a report, titled, "[Telmisartan Market](#) by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027." According to the report, the global telmisartan market size generated \$3.45 billion in 2019, and is expected to reach \$4.25 billion by 2027, manifesting a CAGR of 3.4% from 2020 to 2027.



Telmisartan Market



Telmisartan Market by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies)"

Allied Market Research

For Right Perspective and Competitive Insights, Get Sample Report at: <https://www.alliedmarketresearch.com/request-sample/10658>

Drivers, restraints, and opportunities-

Growth in geriatric population all across the globe, rise in healthcare expenditure, increase in awareness regarding treatment of high blood pressure, and surge in prevalence of hypertension across the globe fuel the growth of the global telmisartan market. However, drug shortages of

telmisartan tablets hinder the market growth. On the other hand, high growth potential in developing countries is expected to create new opportunities in the next few years.

The outbreak of covid-19 impacted the manufacturing facilities and disrupted the supply chain, thereby creating a shortage of telmisartan tablets.

However, as lockdown regulations are getting eased off and most countries are undergoing unlock phases, the industry is expected to recoup soon.

The hypertension segment to maintain its lead position during the forecast period

Based on indication, the hypertension segment held the highest market share in 2019, accounting for around 90% of the global telmisartan market, and is estimated to maintain its lead position during the forecast period. This is owing to rise in prevalence of hypertension patients across the globe and increase in demand for antihypertensive drugs. On the other hand, the cardiovascular risk reduction segment is projected to portray the highest CAGR of 4.3% from 2020 to 2027. This is attributed to factors including increase in prevalence of cardiovascular diseases, rise in government awareness towards cardiovascular risk reduction treatments, growth in geriatric population worldwide as elderly people are highly susceptible to cardiovascular disorders, and surge in demand for effective drugs and therapy for cardiovascular diseases.

Get Detailed COVID-19 Impact Analysis on the Telmisartan Market @

<https://www.alliedmarketresearch.com/request-for-customization/10658?reqfor=covid>

The hospital pharmacies segment to maintain its lead position during the forecast period

Based on distribution channel, the hospital pharmacies segment accounted for the highest market share in 2019, contributing to more than half of the global telmisartan market, and is expected to maintain its lead position during the forecast period. This is due to convenience offers provided by them and strong presence of hospital pharmacies across the globe. On the other hand, the online pharmacies segment is expected to manifest the fastest CAGR of 4.5% from 2020 to 2027. This is owing to increase in preference for online purchasing of drugs over the traditional methods.

North America to maintain the lead by 2027

Based on region, North America contributed to the highest share in 2019, accounting for more than one-third of the global telmisartan market, and is projected to maintain its leadership status by 2027. This is due to rise in number of hypertension patients, surge in adoption of antihypertensive drugs, availability of advanced healthcare facilities with trained medical professionals, and rise in number of hospital pharmacies and online pharmacies. On the other hand, the market across Asia-Pacific is projected to maintain the fastest CAGR of 5.2% during the forecast period, owing to presence of a large potential patient base coupled with surge in new drug launch and rise in use of hypertensive drugs, and rise in prevalence of hypertension and cardiovascular diseases.

Make Purchase Inquiry @ <https://www.alliedmarketresearch.com/purchase-enquiry/10658>

Leading market players

Abbott Laboratories

Aurobindo Pharma

Boehringer Ingelheim International GmbH

Cipla Inc.

Glaxosmithkline Plc (GSK)

Mylan N.V.

Sanofi

Sun Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd. (Actavis Generics)

Zydus Cadila.

Similar Exclusive Reports:

[In Vitro Lung Model Market](#): Global Opportunity Analysis and Industry Forecast 2020–2027

[Medical oxygen concentrators and oxygen cylinders Market](#): Global Opportunity Analysis and Industry Forecast 2020–2027

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: <https://www.alliedmarketresearch.com>

Follow Us on LinkedIn: <https://www.linkedin.com/company/allied-market-research>

David Correa

Allied Analytics LLP

+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552389890>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.